Monday, September 27, 2021 Daily Archives

Cell Therapy Production: A Comprehensive Look at Key Elements of Success

by

Cell therapies offer tremendous potential to treat diseases for which there is often no treatment available. The global cell therapy market is strong and continues to expand. Market research predicts an annual growth rate of 5.4% reaching $8.83 billion by 2027. Cell and gene therapies continue to progress through the clinical pipeline with new cell therapy product approvals, expansion of approved indications for current products, as well as increasing awareness, acceptance, and use of these advanced biological products globally. This…

September 27, 2021

Improve Productivity and Operational Efficiency with Single-Use Technology

by

This webcast features: Rob Martindale, Product Manager, EMEA, Masterflex In many manufacturing environments, and especially in the biopharmaceutical market, there is a constant emphasis on making productivity improvements and streamlining every-day processes. One solution that many companies are turning to is the implementation of single-use technology. In this webinar, we will expand on what’s possible with single-use technology and then highlight practical ways single-use technology can make positive impacts on your workflow and on your bottom line. Just fill out…

September 27, 2021

Boston Labs and Germfree launch mobile CGT platform

by

Boston Labs and Germfree Laboratories have partnered to launch a mobile cell and gene therapy (CGT) manufacturing platform in Boston, US. The partnership between clinical logistics firm, Boston Labs, and manufacturer of mobile and modular laboratories, Germfree, aims to reduce client CGT production expenses and complexities by delivering access to mobile manufacturing facilities wherever they are required. The CGT mobile manufacturing platform will be launched in the fourth quarter of 2021 in Boston, Massachusetts offering a decentralized cell and gene therapy…

September 27, 2021

Quell bolsters manufacturing capabilities with CGT Catapult collaboration

by

Quell Therapeutics has partnered with Cell and Gene Therapy Catapult expanding its manufacturing capabilities to develop engineered T-regulatory cell therapies. The collaboration will see T-regulatory (Treg) cell therapy firm, Quell, bolster its clinical manufacturing capacity and capabilities at Cell and Gene Therapy Catapult’s (CGT Catapult) recently opened large-scale production facility in Stevenage, UK. “By collaborating with CGT Catapult at the manufacturing innovation center in Stevenage, Quell can setup additional GMP manufacturing operations benefitting from infrastructure, expertise and a surrounding cell…

September 27, 2021

Clean Cells bulks up French QC and cell bank production

by

An investment of €13 million ($15.3 million) will create Europe’s largest site in Europe for biopharmaceuticals quality control services, says Clean Cells. Clean Biologics group subsidiary Clean Cells has begun constructing a facility set to quadruple its analysis and production capacity for biopharmaceuticals. The project has financial backing from healthcare investment fund ArchiMed, and the facility in Montaigu-Vendée, France is expected to be complete in September 2022, creating 80 new jobs in the region. “What motivated this expansion is the…

September 27, 2021

Novartis boosts optogenetics portfolio with Arctos buy

by

Novartis will bolster is adeno-associated virus (AAV) gene therapy-based options for different forms of blindness through the acquisition of Arctos Medical. Swiss pharma giant Novartis has acquired gene therapy firm Arctos for an undisclosed fee, gaining one pre-clinical optogenetic AAV gene therapy program and its technology platform. Optogenetics uses light to modulate molecular events in a targeted manner in organisms or living cells and according to Novartis the acquisition supports its commitment to using optogenetics-based therapies to restore vision to patients…

September 27, 2021